CJC-1295 and Ipamorelin: GH Secretagogues

TL;DR: CJC-1295 and ipamorelin are two different growth hormone secretagogues that both push the pituitary to release growth hormone — through different receptors. Combined, they produce a larger, synergistic release than either alone, because they act on complementary parts of the same control system. Everything below is research context; Helix North does not currently supply these peptides.

CJC-1295: A Synthetic GHRH

CJC-1295 is a lab-made analog of growth hormone-releasing hormone (GHRH), the signal the brain uses to tell the pituitary to release growth hormone. It binds the GHRH receptor on pituitary cells and triggers growth hormone release in pulses.

The DAC version (Drug Affinity Complex) carries an extra chemical tail that locks onto serum albumin in the blood, extending its half-life from minutes to days. The non-DAC version — often called Mod GRF 1-29 — keeps the GHRH activity but skips the albumin tail, so it clears faster and produces sharper, more pulse-like bursts. Choosing between them is a research-design decision about pulse shape and duration.

Ipamorelin: A Cleaner GHRP

Ipamorelin is a different class of peptide — a growth hormone-releasing peptide (GHRP). Rather than the GHRH receptor, it acts on the ghrelin receptor (GHS-R1a). Ghrelin is best known as the hunger hormone, but its receptor also strongly drives growth hormone release.

What makes ipamorelin notable is its selectivity. Older GHRPs like GHRP-2 and GHRP-6 also raised cortisol, prolactin and hunger signaling; ipamorelin, at typical research concentrations, produces growth hormone release without those extras.

Why Combine Them?

Natural growth hormone release is controlled by two opposing systems: GHRH (the accelerator) and somatostatin (the brake). Ghrelin signaling does two useful things — it directly stimulates release, and it appears to suppress the somatostatin brake.

So pairing a GHRH-like peptide (CJC-1295) with a ghrelin-like peptide (ipamorelin) hits both sides at once: more accelerator, less brake. The combined release is bigger than the sum of either peptide alone — a true synergy rather than simple addition.

Synergistic growth hormone release from GHRH+GHRP pairing is one of the most consistent findings across decades of pituitary research, replicated across many independent labs.

CJC-1295 vs Ipamorelin at a Glance

Peptide	Class	Receptor	Research role
CJC-1295	GHRH analog	GHRH receptor	Sustained GH pulses · the accelerator
Ipamorelin	Selective GHRP	Ghrelin / GHS-R1a	GH release + eases the somatostatin brake

Research Handling & Reconstitution

Both peptides ship as freeze-dried powder for reconstitution with bacteriostatic water; a reconstitution calculator handles the concentration math. Refrigerate after mixing, keep out of light, and split into aliquots to minimize freeze-thaw exposure — see the peptide storage and handling guide for detail. These are handling mechanics for laboratory use only — not dosing recommendations, and not for human use.

Research Status & Availability

CJC-1295 and ipamorelin are among the most-studied growth hormone secretagogues, but Helix North does not currently carry them. Researchers studying recovery and tissue-repair peptides can explore BPC-157 and TB-500, while those working on metabolic peptides can review the GLP research peptide line. Browse the full Canadian research peptides range for what is in stock.

For Research Use Only

All discussion above describes in-vitro and animal-model laboratory research. Any peptide Helix North supplies is provided strictly for research use — not for human or animal consumption.

Sources and Further Reading

Selected primary literature and official records used for this article. See our editorial standards for sourcing and corrections.

Source list checked August 25, 2026.

Frequently Asked Questions

What are CJC-1295 and ipamorelin?

CJC-1295 and ipamorelin are growth hormone secretagogues — research peptides that prompt the pituitary to release growth hormone. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH); ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor. They are studied as a synergistic pair. Helix North discusses them as research compounds only and does not currently supply them.

Why are CJC-1295 and ipamorelin combined in research?

Natural growth hormone release is governed by an accelerator (GHRH) and a brake (somatostatin). CJC-1295 pushes the accelerator via the GHRH receptor, while ipamorelin both stimulates release through the ghrelin receptor and appears to ease the somatostatin brake. Hitting both sides produces a larger, synergistic growth hormone pulse than either peptide alone — one of the most replicated findings in pituitary research.

What is the difference between CJC-1295 DAC and Mod GRF 1-29?

CJC-1295 DAC carries a Drug Affinity Complex tail that binds serum albumin, extending its half-life from minutes to days for a sustained effect. The non-DAC form, often called Mod GRF 1-29, keeps the GHRH activity but clears quickly, producing sharper, more pulse-like growth hormone bursts. The choice between them is a research-design decision about pulse shape and duration.

How is ipamorelin different from GHRP-2 and GHRP-6?

All three are growth hormone-releasing peptides, but ipamorelin is the most selective. Older GHRPs such as GHRP-2 and GHRP-6 also raise cortisol, prolactin and hunger signaling; ipamorelin, at typical research concentrations, drives growth hormone release without those additional effects — which is why it is favored as a cleaner research tool.

Does Helix North sell CJC-1295 or ipamorelin?

No — Helix North does not currently carry growth hormone secretagogues. Researchers studying recovery and tissue-repair peptides can explore BPC-157 and TB-500, and those studying metabolic peptides can look at the GLP research peptide line. Any peptide Helix North supplies is provided strictly for laboratory research, not for human use.